New hope for PTSD? antidepressant vilazodone put to the test
Symptom relief
Not yet recruiting
This Phase 2 study tests whether the antidepressant vilazodone can safely reduce PTSD symptoms in 200 active-duty service members, veterans, and civilians. Participants receive either vilazodone or a placebo for 12 weeks, with symptom severity measured using a standard PTSD scale…
Phase: PHASE2 • Sponsor: Global Coalition for Adaptive Research • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC